Article

Creating a compliant and scalable CGT logistics launch plan

As cell and gene therapies (CGTs) move from clinical trials to commercial launches, biopharmaceutical companies need to address complex logistical challenges with a strategy that’s customized to their product. Assessing their product’s requirements — such as for temperature controls and regulatory compliance — will ensure a smoother end-to-end delivery and help avoid supply chain disruptions.

The logistics decisions that you need to make when commercializing your cell or gene therapy are complex. Read six expert tips for handling them — from cryogenic shipping to biohazard disposal.

Fill out the form below to read article

Pardot Form

Connect with our cell and gene experts

Our tailored solutions address the unique challenges of advanced therapies, from early discovery through to patient delivery, ensuring that innovative treatments reach those who need them most. Connect with our expert team today to learn how Cencora can support your product’s journey.
Abstract

Related resources

Watch our webinar: A smarter playbook for specialty pharmaceutical launches

Webinar

A smarter playbook for specialty pharmaceutical launches
New Cencora logistics center in Germany

Article

Cencora expands European 3PL capacity with new Dortmund logistics center
abstracts-pathfinder

Article

Demand planning in an evolving pharmaceutical supply chain